Krystal Biotech buy Guggenheim
Start price
27.02.24
/
50%
€152.00
Target price
27.02.25
€161.18
Performance (%)
14.14%
End price
28.02.25
€173.50
Summary
This prediction ended on 28.02.25 with a price of €173.50. The prediction had a final performance of 14.14%. Guggenheim has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | 0.644% | 0.644% | 27.478% |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% |
Comments by Guggenheim for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $130.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten